2. Academic Validation
  3. The novel ROCK2 selective inhibitor NRL-1049 preserves the blood-brain barrier after acute injury

The novel ROCK2 selective inhibitor NRL-1049 preserves the blood-brain barrier after acute injury

  • J Cereb Blood Flow Metab. 2024 Jun 4:271678X241238845. doi: 10.1177/0271678X241238845.
Inge A Mulder 1 2 3 4,  Matt Abbinanti 5,  Sarah A Woller 5,  Joerg Ruschel 5,  Jonathan M Coutinho 4 6,  Helga E de Vries 4 7,  Ed van Bavel 2 3 4,  Kenneth Rosen 5,  Lisa McKerracher 5 8,  Cenk Ayata 1 9
Affiliations

Affiliations

  • 1 Neurovascular Research Unit, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • 2 Department of Biomedical Engineering and Physics, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands.
  • 3 Amsterdam Cardiovascular Sciences, Microcirculation, Amsterdam, the Netherlands.
  • 4 Amsterdam Neurosciences, Neurovascular Disorders, Amsterdam, the Netherlands.
  • 5 BioAxone BioSciences Inc, Boston, MA, USA.
  • 6 Department of Neurology, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands.
  • 7 Department of Molecular Cell Biology and Immunology, Amsterdam UMC location Vrije Universiteit, Amsterdam, the Netherlands.
  • 8 Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.
  • 9 Stroke Service, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
PMID: 38833563 DOI: 10.1177/0271678X241238845
Abstract

Endothelial blood-brain barrier (BBB) dysfunction is critical in the pathophysiology of brain injury. Rho-associated protein kinase (ROCK) activation disrupts BBB integrity in the injured brain. We aimed to test the efficacy of a novel ROCK2 Inhibitor in preserving the BBB after acute brain injury. We characterized the molecular structure and pharmacodynamic and pharmacokinetic properties of a novel selective ROCK2 Inhibitor, NRL-1049, and its first metabolite, 1-hydroxy-NRL-1049 (referred to as NRL-2017 hereon) and tested the efficacy of NRL-1049 on the BBB integrity in rodent models of acute brain injury. Our data show that NRL-1049 and NRL-2017 both inhibit ROCK activity and are 44-fold and 17-fold more selective towards ROCK2 than ROCK1, respectively. When tested in a mouse model of cortical cryoinjury, NRL-1049 significantly attenuated the increase in water content. Interestingly, 60% of the mice in the vehicle arm developed seizures within 2 hours after cryoinjury versus none in the NRL-1049 arm. In spontaneously hypertensive rats, NRL-1049 attenuated the dramatic surge in Evans Blue extravasation compared with the vehicle arm after transient middle cerebral artery occlusion. Hemorrhagic transformation was also reduced. We show that NRL-1049, a selective ROCK2 Inhibitor, is a promising drug candidate to preserve the BBB after brain injury.

Keywords

ROCK; Rho-associated kinase; acute brain injury; blood-brain barrier; ischemic stroke.

Figures
Products